Cargando…
Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation
BACKGROUND: Hypofractionated stereotactic radiotherapy (HFSRT) is indicated for large brain metastases (BM) or proximity to critical organs (brainstem, chiasm, optic nerves, hippocampus). The primary aim of this study was to assess factors influencing BM local control after HFSRT. Then the effect of...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164358/ https://www.ncbi.nlm.nih.gov/pubmed/32303236 http://dx.doi.org/10.1186/s13014-020-01517-3 |
_version_ | 1783523277902184448 |
---|---|
author | Mengue, Laurence Bertaut, Aurélie Ngo Mbus, Louise Doré, Mélanie Ayadi, Myriam Clément-Colmou, Karen Claude, Line Carrie, Christian Laude, Cécile Tanguy, Ronan Blanc, Julie Sunyach, Marie-Pierre |
author_facet | Mengue, Laurence Bertaut, Aurélie Ngo Mbus, Louise Doré, Mélanie Ayadi, Myriam Clément-Colmou, Karen Claude, Line Carrie, Christian Laude, Cécile Tanguy, Ronan Blanc, Julie Sunyach, Marie-Pierre |
author_sort | Mengue, Laurence |
collection | PubMed |
description | BACKGROUND: Hypofractionated stereotactic radiotherapy (HFSRT) is indicated for large brain metastases (BM) or proximity to critical organs (brainstem, chiasm, optic nerves, hippocampus). The primary aim of this study was to assess factors influencing BM local control after HFSRT. Then the effect of surgery plus HFSRT was compared with exclusive HFSRT on oncologic outcomes, including overall survival. MATERIALS AND METHODS: Retrospective study conducted in Léon Bérard Cancer Center, included patients over 18 years-old with BM, secondary to a tumor proven by histology and treated by HFSRT alone or after surgery. Three different dose-fractionation schedules were compared: 27 Gy (3 × 9 Gy), 30 Gy (5 × 6 Gy) and 35 Gy (5 × 7 Gy), prescribed on isodose 80%. Primary endpoint were local control (LC). Secondary endpoints were overall survival (OS) and radionecrosis (RN) rate. RESULTS: A total of 389 patients and 400 BM with regular MRI follow-up were analyzed. There was no statistical difference between the different dose-fractionations. On multivariate analysis, surgery (p = 0.049) and size (< 2.5 cm) (p = 0.01) were independent factors improving LC. The 12 months LC was 87.02% in the group Surgery plus HFSRT group vs 73.53% at 12 months in the group HFSRT. OS was 61.43% at 12 months in the group Surgery plus HFSRT group vs 50.13% at 12 months in the group HFSRT (p < 0.0085). Prior surgery (OR = 1.86; p = 0.0028) and sex (OR = 1.4; p = 0.0139) control of primary tumor (OR = 0.671, p = 0.0069) and KPS < 70 (OR = 0.769, p = 0.0094) were independently predictive of OS. The RN rate was 5% and all patients concerned were symptomatic. CONCLUSIONS: This study suggests that HFSRT is an efficient and well-tolerated treatment. The optimal dose-fractionation remains difficult to determine. Smaller size and surgery are correlated to LC. These results evidence the importance of surgery for larger BM (> 2.5 cm) with a poorer prognosis. Multidisciplinary committees and prospective studies are necessary to validate these observations. |
format | Online Article Text |
id | pubmed-7164358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71643582020-04-22 Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation Mengue, Laurence Bertaut, Aurélie Ngo Mbus, Louise Doré, Mélanie Ayadi, Myriam Clément-Colmou, Karen Claude, Line Carrie, Christian Laude, Cécile Tanguy, Ronan Blanc, Julie Sunyach, Marie-Pierre Radiat Oncol Research BACKGROUND: Hypofractionated stereotactic radiotherapy (HFSRT) is indicated for large brain metastases (BM) or proximity to critical organs (brainstem, chiasm, optic nerves, hippocampus). The primary aim of this study was to assess factors influencing BM local control after HFSRT. Then the effect of surgery plus HFSRT was compared with exclusive HFSRT on oncologic outcomes, including overall survival. MATERIALS AND METHODS: Retrospective study conducted in Léon Bérard Cancer Center, included patients over 18 years-old with BM, secondary to a tumor proven by histology and treated by HFSRT alone or after surgery. Three different dose-fractionation schedules were compared: 27 Gy (3 × 9 Gy), 30 Gy (5 × 6 Gy) and 35 Gy (5 × 7 Gy), prescribed on isodose 80%. Primary endpoint were local control (LC). Secondary endpoints were overall survival (OS) and radionecrosis (RN) rate. RESULTS: A total of 389 patients and 400 BM with regular MRI follow-up were analyzed. There was no statistical difference between the different dose-fractionations. On multivariate analysis, surgery (p = 0.049) and size (< 2.5 cm) (p = 0.01) were independent factors improving LC. The 12 months LC was 87.02% in the group Surgery plus HFSRT group vs 73.53% at 12 months in the group HFSRT. OS was 61.43% at 12 months in the group Surgery plus HFSRT group vs 50.13% at 12 months in the group HFSRT (p < 0.0085). Prior surgery (OR = 1.86; p = 0.0028) and sex (OR = 1.4; p = 0.0139) control of primary tumor (OR = 0.671, p = 0.0069) and KPS < 70 (OR = 0.769, p = 0.0094) were independently predictive of OS. The RN rate was 5% and all patients concerned were symptomatic. CONCLUSIONS: This study suggests that HFSRT is an efficient and well-tolerated treatment. The optimal dose-fractionation remains difficult to determine. Smaller size and surgery are correlated to LC. These results evidence the importance of surgery for larger BM (> 2.5 cm) with a poorer prognosis. Multidisciplinary committees and prospective studies are necessary to validate these observations. BioMed Central 2020-04-17 /pmc/articles/PMC7164358/ /pubmed/32303236 http://dx.doi.org/10.1186/s13014-020-01517-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Mengue, Laurence Bertaut, Aurélie Ngo Mbus, Louise Doré, Mélanie Ayadi, Myriam Clément-Colmou, Karen Claude, Line Carrie, Christian Laude, Cécile Tanguy, Ronan Blanc, Julie Sunyach, Marie-Pierre Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation |
title | Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation |
title_full | Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation |
title_fullStr | Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation |
title_full_unstemmed | Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation |
title_short | Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation |
title_sort | brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after cyberknife installation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164358/ https://www.ncbi.nlm.nih.gov/pubmed/32303236 http://dx.doi.org/10.1186/s13014-020-01517-3 |
work_keys_str_mv | AT menguelaurence brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation AT bertautaurelie brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation AT ngombuslouise brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation AT doremelanie brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation AT ayadimyriam brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation AT clementcolmoukaren brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation AT claudeline brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation AT carriechristian brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation AT laudececile brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation AT tanguyronan brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation AT blancjulie brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation AT sunyachmariepierre brainmetastasestreatedwithhypofractionatedstereotacticradiotherapy8yearsexperienceaftercyberknifeinstallation |